Compare Fresenius Kabi Onco. with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PROCTER & GAMBLE HEALTH - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PROCTER & GAMBLE HEALTH FRESENIUS KABI ONCO./
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 22.1 17.0 129.9% View Chart
P/BV x 3.1 6.9 45.4% View Chart
Dividend Yield % 0.0 6.9 -  

Financials

 FRESENIUS KABI ONCO.   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PROCTER & GAMBLE HEALTH
Dec-18
FRESENIUS KABI ONCO./
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1763,549 5.0%   
Low Rs791,301 6.0%   
Sales per share (Unadj.) Rs37.7511.4 7.4%  
Earnings per share (Unadj.) Rs5.161.3 8.3%  
Cash flow per share (Unadj.) Rs6.774.0 9.1%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs42.5927.8 4.6%  
Shares outstanding (eoy) m158.2316.60 953.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.7 71.2%   
Avg P/E ratio x25.039.6 63.1%  
P/CF ratio (eoy) x18.932.8 57.8%  
Price / Book Value ratio x3.02.6 114.4%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m20,13540,257 50.0%   
No. of employees `0001.21.1 101.6%   
Total wages/salary Rs m7031,313 53.6%   
Avg. sales/employee Rs Th5,176.27,486.7 69.1%   
Avg. wages/employee Rs Th610.41,157.6 52.7%   
Avg. net profit/employee Rs Th699.6897.2 78.0%   
INCOME DATA
Net Sales Rs m5,9638,490 70.2%  
Other income Rs m18244 7.4%   
Total revenues Rs m5,9818,734 68.5%   
Gross profit Rs m1,4301,482 96.5%  
Depreciation Rs m258211 122.1%   
Interest Rs m-260-   
Profit before tax Rs m1,2161,514 80.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-6866 -103.8%   
Tax Rs m342563 60.8%   
Profit after tax Rs m8061,017 79.2%  
Gross profit margin %24.017.5 137.4%  
Effective tax rate %28.137.1 75.7%   
Net profit margin %13.512.0 112.8%  
BALANCE SHEET DATA
Current assets Rs m5,10215,343 33.3%   
Current liabilities Rs m2,3851,960 121.7%   
Net working cap to sales %45.6157.6 28.9%  
Current ratio x2.17.8 27.3%  
Inventory Days Days15049 307.9%  
Debtors Days Days11328 398.2%  
Net fixed assets Rs m5,1481,209 425.7%   
Share capital Rs m158166 95.3%   
"Free" reserves Rs m6,55615,235 43.0%   
Net worth Rs m6,73215,401 43.7%   
Long term debt Rs m9520-   
Total assets Rs m10,38817,595 59.0%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.5 119.0%   
Return on assets %7.55.8 129.8%  
Return on equity %12.06.6 181.2%  
Return on capital %14.610.3 142.4%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2981,636 323.8%   
Fx outflow Rs m1,7724,368 40.6%   
Net fx Rs m3,525-2,732 -129.1%   
CASH FLOW
From Operations Rs m1,274-1,304 -97.7%  
From Investments Rs m-1,20412,697 -9.5%  
From Financial Activity Rs m-196-301 65.3%  
Net Cashflow Rs m-12611,093 -1.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 51.8 156.4%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 9.6 1.0 960.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   42,599 28,591 149.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   GLENMARK PHARMA  FULFORD INDIA  ORCHID PHARMA  DIVIS LABORATORIES  UNICHEM LAB  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Equity Mutual Fund Inflows in March, RBI's First Purchase Under G-SAP 1.0, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended marginally lower on Friday last week. At the closing bell on Friday, the BSE Sensex stood lower by 154 points (down by 0.3%).

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS